Von Willebrand factor and JAK2V617F variant allele frequency predict thrombosis and bleeding in patients with myeloproliferative neoplasms
Authors:
Open Access
- 14 October 2025
- journal article
- research article
- Published by Springer Nature in Annals of Hematology
- Vol. 104 (10) , 5085-5094
Abstract
Thrombosis is a major cause of morbidity and mortality in patients with myeloproliferative neoplasms (MPN), while bleeding is also common. Current thrombosis and bleeding risk stratification strategies are limited, creating a need for identification of novel risk factors to better predict these complications. We performed laboratory coagulation testing and driver mutation profiling from peripheral blood of patients with MPN. Patients’ history of comorbidities, hematological variables and thrombosis and/or bleeding events were collected retrospectively at the time of testing. Patients were then followed for a median of 3.3 years for incident events. 198 patients were included in the study. Thrombotic events occurred in 41% of the patients. Age, cardiovascular comorbidities and constitutional symptoms were significantly associated with thrombosis, as well as elevated von Willebrand Factor (vWF): Antigen, vWF: Activity and factor VIII levels. Elevated vWF: Antigen levels remained independent in multivariate analysis and were predictive of incident thrombosis. Bleeding events occurred in 26% of the patients. vWF: Activity ≤ 30%, vWF: Activity-to-antigen ratio of ≤ 0.7, a platelet count of ≥ 500*10 9 /L and JAK2 V617F variant allele frequency (VAF) of ≥ 50% were predictive of total (including minor) bleeding events. However, only JAK2 V617F VAF of ≥ 50% was predictive of major and clinically relevant non-major bleeding. Extreme thrombocytosis defined by a platelet count of ≥ 1000*10 9 /L was not associated with bleeding or acquired vWF syndrome. vWF profiling and JAK2 V617F VAF contribute to thrombosis and bleeding risk assessment in patients with MPNs and should be incorporated routinely at diagnosis and during follow-up.Keywords
Funding Information
- Hebrew University of Jerusalem
This publication has 35 references indexed in Scilit:
- Thromboses and hemorrhages are common in MPN patients with high JAK2V617F allele burdenAnnals of Hematology, 2017
- Factors related to the development of acquired von Willebrand syndrome in patients with essential thrombocythemia and polycythemia veraEuropean Journal of Internal Medicine, 2017
- Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyureaHaematologica, 2016
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemiaBlood, 2016
- Spleen enlargement is a risk factor for thrombosis in essential thrombocythemia: Evaluation on 1,297 patientsAmerican Journal of Hematology, 2016
- JAK2V617F monitoring in polycythemia vera and essential thrombocythemia: Clinical usefulness for predicting myelofibrotic transformation and thrombotic eventsAmerican Journal of Hematology, 2014
- Von Willebrand Factor in Cardiovascular DiseaseCirculation, 2008
- Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation statusBlood, 2006
- Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patientsJournal of Thrombosis and Haemostasis, 2005
- The factor VIII/von Willebrand factor complex: basic and clinical issues.2003